Drug firms need to tackle affordabilityBMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i6096 (Published 14 November 2016) Cite this as: BMJ 2016;355:i6096
- Anne Gulland
Drug companies need to do more to make their products affordable to patients in low and middle income countries, an investigation into drug firms’ access to medicines policies has found.
The Access to Medicines Index, which is published every two years and ranks companies according to how they make their products available to patients in poorer countries, found little progress in improving affordability.1
There are currently 850 products on the market for the 51 most burdensome diseases in low and middle income countries. Companies are developing another 420, which includes more than 100 products that have entered the pipeline since 2014 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial